# Dapagliflozin in Respiratory Failure in Patients With COVID-19

> **NCT04350593** · PHASE3 · COMPLETED · sponsor: **Saint Luke's Health System** · enrollment: 1250 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Dapagliflozin 10 milligram (mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04350593
- **Lead sponsor:** Saint Luke's Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-22
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-06-11
- **Target enrollment:** 1250 (ACTUAL)
- **Last updated:** 2022-06-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04350593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04350593, "Dapagliflozin in Respiratory Failure in Patients With COVID-19". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04350593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*